81
Participants
Start Date
August 31, 2012
Primary Completion Date
December 31, 2015
Study Completion Date
December 31, 2015
Erlotinib
Erlotinib 150 mg/day p.o. continuously with 21 days cycle.
Docetaxel
Docetaxel 75 mg/m2 as an IV infusion every 21 days.
Fondation du centre Pluridisciplinaire d'Oncologie (CePO), Lausanne
Onkologiezentrum Berner Oberland, Thun
University Hospital Basel, Basel
Kantonsspital Luzern, Lucerne
Hospital 12 de Octubre, Madrid
Krankenhaus Hietzing, Vienna
Institut Jules Bordet, Brussels
Aarhus University Hospital, Aarhus
University Hospital of Heraklion, Heraklion
National Institute of Oncology, Budapest
St James's Hospital, Dublin
Institution Rabin MC, Petah Tikwa
Tel-Aviv Medical Center, Tel Aviv
Medical Oncology, Second University Naples, Naples
Vercelli Teaching Hospital, Vercelli
Hospital general de Alicante, Alicante
Institut Català d'Oncologia - L'Hospitalet, Barcelona
Hospital San Pedro de Alcantara, Cáceres
Ciudad Real General University Hospital, Ciudad Real
Onkologikoa, Donostia / San Sebastian
Hospital Severo Ochoa, Leganés
Carlos Haya Hospital, Málaga
Hospital Universitari Sant Joan, Reus
Hospital Arnau Vilanova Valencia, Valencia
Hospital Clínico Universitario de Valencia, Valencia
Hospital La Fe, Valencia
Kantonsspital Graubünden, Chur
Universitätsspital Zürich, Zurich
University Hospital South Manchester, Manchester
Weston Park Hospital, Sheffield
Free University Medical Center, Amsterdam
Hospital Clínic Barcelona, Barcelona
Collaborators (1)
Biodesix, Inc.
INDUSTRY
ETOP IBCSG Partners Foundation
NETWORK